Stockholm, 26th August, 2019 – Peptonic Medical (publ) (“Peptonic” or “Company”) today announced that it has entered an agreement with ADEXILIS Service Kft. (“Adexilis”) concerning the marketing, sales and distribution of VagiVital® in Hungary, Slovakia and Croatia. Under the agreement, Adexilis is granted the exclusive commercial rights to VagiVital® in the above mentioned countries. In return, Adexilis has committed to annual minimum purchase volumes of VagiVital® and to bear all costs for marketing and distribution.
– We are very pleased to have Adexilis as our partner, in fact, the first one for VagiVital® on the European continent, says Dr Johan Inborr, CEO of Peptonic Medical. Adexilis is a fast growing company with a portfolio of innovative women’s health products and well developed sales channels.
Adexilis plans to launch VagiVital® during the first quarter of 2020.
– We are proud to represent VagiVital in Hungary, Slovakia and Croatia. We strive to provide women with innovative, high quality products that represent our values, says Mr Robert Karl, Managing Director of Adexilis. VagiVital is an important milestone for us to be the #1 trusted partner for women and we are excited to bring VagiVital to a growing community of women realizing the true value of hormone-free, effective healthcare.
For more information, please contact;
Johan Inborr, CEO
Mobile: +46 708 853 893
This information is information that Peptonic Medical AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 26th August 2019.
VagiVital®is a patent pending hormone free self-care product for the treatment of vaginal atrophy and vaginal dryness. The product has been tested in randomised clinical studies (vaginal atrophy) with very positive results both for objective (vaginal pH and proportion of superficial cells in the vaginal mucosa) and subjective (most bothersome symptoms, such as vaginal dryness, vaginal irritation/itching, dyspareunia and dysuria) parameters. The magnitude of symptom relief is on par with that demonstrated with e.g. prescription estrogen based products on the market today. It was very well tolerated and caused no serious adverse effects.
VagiVital®was launched in Sweden as a non-prescription self-care product in July 2018 (see www.vagivital.com).
About Peptonic Medical
Peptonic Medical is an innovative Swedish medical development company. Its vision is to offer safe and effective treatments and relief for women specific diseases and medical conditions.
VagiVital®is a registered trademark of Peptonic Medical. The product is hormone free and is being commercialised for the non-prescription use for the treatment of vaginal atrophy (VA) and vaginal dryness. The pipeline of Peptonic Medical also includes Vagitocin®, which is an oxytocin-based vaginal gel for the treatment of VA. This product candidate is in clinical development phase 2. The development of Vagitocin® is on hold pending additional data on i.a. the mechanism of action.
Since July 2014, the Peptonic Medical share has been traded on the Spotlight Stock Exchange (www.spotlightstockmarket.com, ticker: PMED) in Stockholm, Sweden.
For more information:www.peptonicmedical.com
ADEXILIS a privately owned pharmaceutical company engaged in regional representation, BioPartnering and Consulting. While headquartered in Switzerland ADEXILIS has affiliates in a variety of markets in Central Eastern Europe as well as Middle East.
One of our core pillars is Women`s Health where we execute with a true Customer Centric mindset. We put the customer first, taking into account the complexity of today’s world. We seek to understand our customer’s customer needs and provide innovative solutions to enhance our customer’s lives, businesses and gain their trust as a preferred partner. We represent a clear differentiated set of values when it comes to the products we represent.
For more information: www.adexilis.com